Skip to main content

Advertisement

Table 1 Baseline characteristics of patient cohorts

From: Prognostic value of ERBB4 expression in patients with triple negative breast cancer

  Training N = 203 (%) Validation N = 84 (%) p-value
Age (median) 46.4 ± 10.2 46.1 ± 11.0 0.308
 Range 23.5-74.1 22.4 – 74.0  
  < 40 years 48 (23.6) 28 (33.3)  
  ≥ 40 years 155 (76.4) 56 (66.7)  
Histology    0.654
 IDCa 180 (88.7) 76 (90.5)  
 Others 23 (11.3) 8 (9.5)  
Stage    <0.001
 I 55 (27.1) 15 (17.9)  
 IIA 94 (46.3) 18 (21.4)  
 IIB 33 (16.3) 9 (11.9)  
 IIIA 13 (6.4) 26 (31.0)  
 IIIB 0 (0) 1 (1.2)  
 IIIC 8 (3.9) 14 (16.7)  
 Unknown 0 (0) 1 (1.2)  
Nuclear grade    0.191
 1 2 (1.0) 0 (0)  
 2 47 (23.2) 18 (21.4)  
 3 145 (71.4) 57 (67.9)  
 Unknown 9 (4.4) 9 (10.7)  
Histologic grade    0.411
 1 3 (1.5) 1 (1.2)  
 2 45 (22.2) 20 (23.8)  
 3 144 (70.9) 54 (64.3)  
 Unknown 11 (5.4) 9 (10.7)  
RNA expression (log2 scale, median)    
 EGFR 7.0 ± 1.1 7.6 ± 1.2 0.456
 ERBB2 9.0 ± 1.0 9.4 ± 1.6 0.439
 ERBB3 7.2 ± 1.0 7.7 ± 1.0 0.503
 ERBB4 1.3 ± 1.4 2.3 ± 2.2 0.302
 ESR1 4.4 ± 0.1 4.5 ± 2.0 0.425
Chemotherapy    NA
 Adjuvant 203 (100) 60 (71.4)  
 Neoadjuvant 0 (0) 24 (28.6)  
 Unknown 0 (0) 0 (0)  
Regimen    NA
 CMF1 86 (42.4) 10 (11.9)  
 FAC2 58 (28.6) 16 (19.0)  
 AC3 17 (8.4) 5 (6.0)  
 AC –T(H)4 41 (20.2) 46 (54.8)  
 Hormone 0 (0) 0 (0)  
 Unknown 1 (0.5) 7 (8.3)  
Adjuvant RTx5    0.161
 Yes 130 (64.0) 61 (72.6)  
 No 73 (36.0) 23 (27.4)  
  1. aInvasive ductal carcinoma, 1Cyclophosphamide/Methotrexate/Fluorouracil, 2Fluorouracil/Adriamycin/Cyclophosphamide, 3Adriamycin/Cyclophosphamide, 4Taxane (Herceptin), 5Radiotherapy